Masaki Kanazu

Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

Akio Osa, Takeshi Uenami, Shohei Koyama et al. · JCI Insight · 2018 · 234 citations · Full text

Pharmacy, Immunology, Oncology +17

A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib

Naoki Omachi, Shigeki Shimizu, Tomoya Kawaguchi et al. · Journal of Thoracic Oncology · 2014 · 58 citations · Full text

Medicine, Oncology, Pathology +17

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya et al. · Investigational New Drugs · 2019 · 54 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya et al. · Investigational New Drugs · 2019 · 53 citations

Pharmacy, Oncology, Pharmacotherapy +16

Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report

Takeshi Uenami, Yuki Hosono, Mikako Ishijima et al. · Lung Cancer · 2017 · 48 citations

Medicine, Oncology, Pharmacotherapy +8